Reasons why some children receiving tacrolimus therapy require steroids more than 5 years post liver transplantation

Pediatric Transplantation

Volumn 5, Issue 2, 2001, Pages 93-98

  Jain, Ashok ^a,b   Mazariegos, George ^a,b   Kashyap, Randeep ^a,b   Marsh, Wallis ^a,b   Khanna, Ajay ^a,c   Iurlano, Kathy ^a,b   Fung, John ^a,b   Reyes, Jorge ^a,b,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Department of Surgery ^*  (United States)

^c UNIVERSITY OF SAN DIEGO   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Children; Liver transplantation; Steroid; Tacrolimus

Indexed keywords

PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ARTICLE; BRAIN EDEMA; CHILD; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; STEROID THERAPY;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; PREDNISONE; TACROLIMUS; TIME FACTORS;

EID: 0035052150     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.005002093.x     Document Type: Article

References (24)

1. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
2. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK506
3. Randomised trialomania? The multicentre liver transplant trials of tacrolimus
4. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group
5. One thousand consecutive primary orthotopic liver transplants under FK506: Survival and adverse events
6. Risks and benefits of weaning immunosuppression in liver transplant recipients: Long-term follow-up
7. Weaning of immunosuppression in liver transplant recipients
8. Liver transplantation under tacrolimus in infants, children, adults, and seniors: Long-term results, survival, and adverse events in 1000 consecutive patients
9. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term Follow-up of the first 1000 patients
10. Comparative long-term evaluation of cyclosporine and tacrolimus in pediatric liver transplantation
11. Terminology For hepatic allograft rejection
12. Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients
13. The necessity for steroid induction or longterm maintenance after liver transplantation: The argument against
14. Early steroid withdrawal in liver transplantation is safe and beneficial
15. Successful prednisone withdrawal after living-related liver transplantation
16. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: A prospective trial of cyclosporine and tacrolimus
17. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: Experience with a steroid-sparing concept
18. A randomized prospective trial of steroid withdrawal after liver transplantation
19. Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients
20. Steroid withdrawal from long-term immunosuppression in liver allograft recipients
21. Corticosteroid withdrawal after liver transplantation
22. Maintenance immunosuppression without steroids in pediatric liver transplantation
23. Steroid withdrawal after pediatric liver transplantation
24. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients